Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study

被引:0
作者
Yan, Xin [1 ]
Huang, Yuanyuan [2 ]
Xie, Jinlian [3 ]
Wu, Qian [3 ]
Yang, Shuang [3 ]
Yang, Xiaoyan [3 ]
Chen, Honghui [3 ]
Huang, Jie [3 ]
Yang, Guoping [1 ,3 ]
机构
[1] Cent South Univ, Xiangya Sch Pharmaceut Sci, Changsha, Hunan, Peoples R China
[2] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
[3] Cent South Univ, Xiangya Hosp 3, Clin Pharmacol Ctr, Changsha, Hunan, Peoples R China
关键词
HRS9432(A); echinocandin-class antifungal drugs; pharmacokinetics; safety; tolerability; dose escalation;
D O I
10.1128/aac.00524-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HRS9432(A) is a long-acting echinocandin antifungal medication primarily used to treat invasive fungal infections, particularly invasive candidiasis. The safety, tolerability, and pharmacokinetic characteristics of HRS9432(A) injection were investigated in a randomized, double-blind, placebo-controlled, single- and multiple-ascending-dose Phase I study involving 56 healthy adult subjects. Doses ranging from 200 to 1200 mg were administered. Safety was continually monitored, including adverse events, clinical laboratory examinations, vital signs, 12-lead electrocardiograms, and physical examinations, while the pharmacokinetic profile within the body was evaluated. The results indicated that concentrations of HRS9432 peaked immediately after infusion, demonstrating essentially linear pharmacokinetic characteristics within the dosage range of 200-1,200 mg. It exhibited a low clearance rate and an extended half-life, with a clearance of approximately 0.2 L/h, a volume of distribution of around 40 L, and a half-life of approximately 140h following a single dose. The accumulation index for AUC0-tau after multiple doses ranged from 1.41 to 1.75. No severe adverse events occurred during the study, and the severity of all adverse events was mild or moderate. Therefore, the intravenous administration of HRS9432(A) in healthy Chinese adult subjects, either as multiple infusions of 200 to 600 mg (once a week, four doses) or as a single infusion of 900-1,200 mg, demonstrated overall good safety and tolerability. The pharmacokinetic exhibited essentially linear characteristics in the body, supporting a weekly dosing frequency for clinical applications and providing additional options for the treatment or prevention of invasive fungal infections.CLINICAL TRIALS This study is registered with the International Clinical Trials Registry Platform as ChiCTR2300073525 .
引用
收藏
页数:11
相关论文
共 9 条
[1]   Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins [J].
Garcia-Effron, Guillermo .
JOURNAL OF FUNGI, 2020, 6 (04) :1-23
[2]  
Morrison Vicki A, 2005, Expert Rev Anti Infect Ther, V3, P697, DOI 10.1586/14787210.3.5.697
[3]   Anidulafungin [J].
Murdoch, D ;
Plosker, GL .
DRUGS, 2004, 64 (19) :2249-2258
[4]   Epidemiology of invasive candidiasis: a persistent public health problem [J].
Pfaller, M. A. ;
Diekema, D. J. .
CLINICAL MICROBIOLOGY REVIEWS, 2007, 20 (01) :133-+
[5]   Elevated Transaminases as Predictors of COVID-19 Pneumonia Severity [J].
Radonjic, Tijana ;
Milicevic, Ognjen ;
Jovanovic, Igor ;
Zdravkovic, Marija ;
Dukic, Marija ;
Mandic, Olga Milorad ;
Bjekic-Macut, Jelica ;
Markovic, Olivera Borko ;
Todorovic, Zoran ;
Brajkovic, Milica ;
Nikolic, Novica ;
Klasnja, Slobodan ;
Popadic, Viseslav ;
Divac, Anica ;
Marinkovic, Milica ;
Alhayek, Nabil ;
Brankovic, Marija Svetislav .
MEDICINA-LITHUANIA, 2022, 58 (07)
[6]   Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults [J].
Sandison, Taylor ;
Ong, Voon ;
Lee, Jonathan ;
Thye, Dirk .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (02)
[7]   Rezafungin: First Approval [J].
Syed, Yahiya Y. .
DRUGS, 2023, 83 (09) :833-840
[8]   Echinocandins - structure, mechanism of action and use in antifungal therapy [J].
Szymanski, Mateusz ;
Chmielewska, Sandra ;
Czyzewska, Urszula ;
Malinowska, Marta ;
Tylicki, Adam .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2022, 37 (01) :876-894
[9]   Invasive Fungal Infection New Treatments to Meet New Challenges [J].
von Lilienfeld-Toal, Marie ;
Wagener, Johannes ;
Einsele, Hermann ;
Cornely, Oliver A. ;
Kurzai, Oliver .
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2019, 116 (16) :271-+